Cyclodextrins Allow the Combination of Incompatible Vancomycin and Ceftazidime into an Ophthalmic Formulation for the Treatment of Bacterial Keratitis.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
29 Sep 2021
Historique:
received: 29 07 2021
revised: 24 09 2021
accepted: 27 09 2021
entrez: 13 10 2021
pubmed: 14 10 2021
medline: 28 10 2021
Statut: epublish

Résumé

Ceftazidime (CZ) and vancomycin (VA) are two antibiotics used to treat bacterial keratitis. Due to their physical incompatibility (formation of a precipitate), it is not currently possible to associate both molecules in a single container for ophthalmic administration. We firstly characterized the incompatibility then investigated if 2-hydroxypropyl-beta (HPβCD) and 2-hydroxypropyl-gamma cyclodextrins (HPγCD) could prevent this incompatibility. The impact of pH on the precipitation phenomena was investigated by analysing the supernatant solution of the mixture using high performance liquid chromatography. A characterization of the inclusion of CZ with HPγCD using

Identifiants

pubmed: 34638878
pii: ijms221910538
doi: 10.3390/ijms221910538
pmc: PMC8508691
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
gamma-Cyclodextrins 0
hydroxypropyl-gamma-cyclodextrin 0
Vancomycin 6Q205EH1VU
Ceftazidime 9M416Z9QNR

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

AAPS PharmSciTech. 2006 Mar;7(1):E33-E37
pubmed: 28290020
Biomolecules. 2019 Sep 25;9(10):
pubmed: 31557949
Toxicol Pathol. 2008 Jan;36(1):30-42
pubmed: 18337219
Int J Pharm. 2020 Apr 15;579:119181
pubmed: 32112928
J Pharm Sci. 1995 May;84(5):534-8
pubmed: 7658340
Molecules. 2018 May 17;23(5):
pubmed: 29772824
Exp Eye Res. 2019 Dec;189:107829
pubmed: 31605685
BMC Ophthalmol. 2017 Nov 25;17(1):212
pubmed: 29178851
J Ophthalmic Vis Res. 2020 Apr 06;15(2):128-137
pubmed: 32308946
Ophthalmology. 2019 Jan;126(1):P1-P55
pubmed: 30366799
PeerJ. 2018 Apr 18;6:e4549
pubmed: 29682408
Surv Ophthalmol. 2019 May - Jun;64(3):255-271
pubmed: 30590103
Int J Pharm. 2017 Oct 15;531(2):413-423
pubmed: 28391041
Pak J Pharm Sci. 2012 Oct;25(4):831-7
pubmed: 23010001
Pharm Weekbl. 1958 Feb 22;93(4):148-55
pubmed: 13542163
J Magn Reson. 2007 Mar;185(1):179-82
pubmed: 17188920
Eur J Pharm Biopharm. 1998 Nov;46(3):355-60
pubmed: 9885309
Am J Ophthalmol Case Rep. 2018 Sep 12;12:73-75
pubmed: 30272036
Ophthalmology. 2017 Nov;124(11):1678-1689
pubmed: 28942073
Antimicrob Agents Chemother. 2001 Sep;45(9):2643-7
pubmed: 11502544
Invest Ophthalmol Vis Sci. 2002 Apr;43(4):1182-8
pubmed: 11923264
Materials (Basel). 2019 Jan 11;12(2):
pubmed: 30641887
Int J Mol Sci. 2013 Feb 07;14(2):3671-82
pubmed: 23434664
BMJ Open Ophthalmol. 2017 Aug;2:
pubmed: 29226254
Acta Ophthalmol. 2020 May;98(3):255-260
pubmed: 31580009
J Pharm Sci. 2021 Feb;110(2):654-664
pubmed: 33069709
J Ocul Pharmacol Ther. 2013 Feb;29(1):23-6
pubmed: 23035974
Retina. 2008 Feb;28(2):320-5
pubmed: 18301038
Commun Dis Intell (2018). 2020 Oct 25;44:
pubmed: 33278871
Pharmaceutics. 2020 Aug 17;12(8):
pubmed: 32824572
Pharmaceutics. 2020 Aug 19;12(9):
pubmed: 32825121
Perit Dial Int. 2002 Jan-Feb;22(1):93-4
pubmed: 11929153
Br J Ophthalmol. 2000 Jan;84(1):117-8
pubmed: 10691328
J Ophthalmic Inflamm Infect. 2020 Nov 27;10(1):35
pubmed: 33245477
Cornea. 2015 May;34(5):560-6
pubmed: 25789693
Eye (Lond). 2021 Apr;35(4):1084-1101
pubmed: 33414529
Pharmaceutics. 2018 Dec 01;10(4):
pubmed: 30513707
Acta Pol Pharm. 2011 Jan-Feb;68(1):99-107
pubmed: 21485707
Turk J Ophthalmol. 2019 Jun 27;49(3):123-129
pubmed: 31245971
Korean J Ophthalmol. 2019 Jun;33(3):296-297
pubmed: 31179663
Arch Ophthalmol. 1993 Jun;111(6):730
pubmed: 8512464
Food Chem. 2016 Apr 1;196:968-75
pubmed: 26593579
Anaesthesia. 2000 Oct;55(10):1039-40
pubmed: 11012529
Basic Clin Pharmacol Toxicol. 2018 Jan;122(1):46-55
pubmed: 29024354

Auteurs

Yassine Bouattour (Y)

Université Clermont Auvergne, CHU Clermont Ferrand, Clermont Auvergne INP, CNRS, ICCF, F-63000 Clermont-Ferrand, France.

Florent Neflot-Bissuel (F)

CHU Clermont-Ferrand, Pôle Pharmacie, F-63000 Clermont-Ferrand, France.

Mounir Traïkia (M)

Université Clermont Auvergne, CNRS, SIGMA-Clermont, ICCF, F-63000 Clermont-Ferrand, France.

Anne-Sophie Biesse-Martin (AS)

Université Clermont Auvergne, CNRS, SIGMA-Clermont, ICCF, F-63000 Clermont-Ferrand, France.

Robin Frederic (R)

Université Clermont Auvergne, Inserm U1071, INRA USC2018, F-63000 Clermont-Ferrand, France.

Mouloud Yessaad (M)

CHU Clermont-Ferrand, Pôle Pharmacie, F-63000 Clermont-Ferrand, France.

Mireille Jouannet (M)

CHU Clermont-Ferrand, Pôle Pharmacie, F-63000 Clermont-Ferrand, France.

Mathieu Wasiak (M)

CHU Clermont-Ferrand, Pôle Pharmacie, F-63000 Clermont-Ferrand, France.

Philip Chennell (P)

Université Clermont Auvergne, CHU Clermont Ferrand, Clermont Auvergne INP, CNRS, ICCF, F-63000 Clermont-Ferrand, France.

Valerie Sautou (V)

Université Clermont Auvergne, CHU Clermont Ferrand, Clermont Auvergne INP, CNRS, ICCF, F-63000 Clermont-Ferrand, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH